Treatments with inhibitors of DGAT1 (A922500, DGAT1i) and DGAT2 (PF-06424439, DGAT2i) activity for 48 h were able to counteract the increase of plasma membrane TGFβ-R1 and TGFβ-R2 levels in Elovl5-depleted breast cancer cells (Fig. 6A, B and Supplementary Fig. S6A). This evidence concerns the gene TGFBR1 and breast carcinoma.